Janssen licenses drug candidates to BenevolentAI

Janssen has licensed a number of its novel clinical stage drug candidates to the leading British artificial intelligence company BenevolentAI.

By licensing these therapies and their extensive related portfolio of patents, BenevolentAI scientists will be able to use their AI technology to evaluate the potential of the small molecule compounds as therapeutic options for hard-to-treat diseases.

BenevolentAI will have the exclusive rights to develop, manufacture and commercialise these novel drug candidates in all indications and in all territories, with late-stage phase IIb clinical trials to be commenced by the company in mid-2017.

Jackie Hunter, board director of BenevolentAI and chief executive officer of BenevolentAI Bio, said: "Securing these novel clinical drug candidates perfectly aligns with our strategy of developing first-in-class and best-in-class stratified medicines to help patients with high unmet needs."

This agreement was facilitated by the Johnson and Johnson Innovation Centre in London, as Janssen is a subsidiary of the wider Johnson and Johnson group.

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.